<DOC>
	<DOCNO>NCT00470340</DOCNO>
	<brief_summary>Besides liver transplantation , curative treatment primary hepatic cancer cirrhosis remain surgical resection . Radiofrequency cryotherapy currently allow local ablation small cancer , good result . However , treatment follow high rate recurrence ( 50 - 70 % 5 year ) . Then , seem essential associate surgical resection local ablation `` adjuvant '' treatment , order prevent decrease rate recurrence . However , evidence support attitude . Therefore , follow curative treatment primary hepatic cancer cirrhosis , propose compare treat untreated patient . Postoperative treatment mean either intra-arterial chemotherapy systemic chemotherapy . The main criterion study time survival without recurrence . The main secondary objective safety .</brief_summary>
	<brief_title>Chemotherapy Not , Following Complete Treatment Hepatic Cancer Cirrhotic Patients</brief_title>
	<detailed_description>The best treatment hepatocellular carcinoma ( HCC ) cirrhosis , currently liver transplantation treat cancer causal disease . For majority patient , transplantation propose , curative treatment remain surgical resection . Radiofrequency cryotherapy currently allow local destruction ( ablation ) small HCC , result seem equivalent surgical resection . These last technique increase therapeutic possibility presence hepatic insufficiency . However , treatment follow high rate recurrence ( 50 - 70 % 5 year close 100 % 10 year ) . The development tumoral nodule , undetected time curative treatment , occurrence new HCC , effect cirrhotic process viral genomic modification explain disappointing result . Therefore , seem essential associate adjuvant treatment surgical resection local destruction . Intra-arterial chemotherapy without embolisation largely evaluate therapeutic approach whose result contradictory . Several retrospective study , seem nevertheless show benefit treatment adjuvant situation . Systemic chemotherapy long time regard ineffective , currently renew interest due use new drug like gemcitabine oxaliplatin ( GEMOX regimen ) . This regimen show certain effect phase II study advance form HCC cirrhosis . We propose test prospective randomize multicentric phase III study , effectiveness adjuvant treatment systemic chemotherapy intra-arterial LIPIODOLISED chemotherapy ( CIAL ) , surgery complete local destruction HCC . Three group compare : group untreated patient ( n=109 ) , group patient treat intra-arterial chemotherapy ( CIAL = cisplatin 75 mg + lipiodol 10 ml ; 3 course every 6 week ) ( n=77 ) group patient treat systemic chemotherapy ( GEMOX= day 1 : gemcitabine 1000 mg/m² iv within 100 min ; day 2 : oxaliplatin 100 mg/m² iv within 2h ; 8 course every 2 week , d1 = d14 ) ( n=77 ) . Selection randomisation plan 4-8 week follow complete treatment HCC . Identical follow 3 group include clinical , biological , morphological exam every 3 month 2 year , every 6 month 3 year . The main criterion study survival without recurrence . The secondary objective global survival , safety estimate cost various treatment . The awaited result 1 ) demonstrate effectiveness least one adjuvant treatment follow complete treatment HCC cirrhotic patient 2 ) determine best adjuvant treatment . Estimated inclusion time 2 year , analysis principal criterion 3 year . Follow-up 5 year envisage patient , lead 7 year duration study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasm Recurrence , Local</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>Hepatocellular carcinoma ( histology Barcelona criterion ) curatively treated surgical resection radiofrequency cryotherapy Evidence liver cirrhosis ( clinical , biological , endoscopic histological criterion ) Morphological evaluation 4 6 week follow curative treatment No evidence local distant disease morphological evaluation Absence peritoneal lymph node metastasis Absence pre peroperative macroscopic tumoral thrombus Minimal free margin 5 mm follow pathological exam ALPHAAFOETOPROTEINE level le 4 normal value decrease 50 % , 4 6 week follow curative treatment Biological criterion , 2 week treatment follow : neutrophilic polymorphonuclear &gt; 1500/mm3 , platelet &gt; 100 000/mm3 , total bilirubin &lt; 25 mmol/l ( 1.46 mg/dl ) , creatinin &lt; 1.5 x normal value Eastern Cooperative Oncology Group ( ECOG ) equal 0 1 Life expectancy &gt; 12 week Absence sensitive neuropathy inclusion time Health insurance coverage Efficient contraceptive method applicable Signed informed consent Curative treatment perform 10 week begin adjuvant treatment Contraindication angiography hepatic artery thrombosis portal thrombosis . Pregnant breastfeed woman Concomitant involvement clinical trial Decompensate cirrhosis ChildPugh score ≥ 8 clinical ascitis . Cancer Liver Italian Program ( C.L.I.P . ) score ≥ 2 Heart lung insufficiency Other cancer consider definitively cured Creatinin clearance &lt; 30 ml/min Recurrence HCC le 12 month follow last treatment Any radiotherapy 4 week inclusion Known sensitivity drug protocol Immunodeficiency ( HIV+ , transplant patient ) Inability follow Impossibility clear understand protocol french speak patient Patient legal protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Recurrence</keyword>
	<keyword>Neoplasm Recurrence , Local</keyword>
	<keyword>Liver</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Liver Cirrhosis</keyword>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Iodized Oil</keyword>
	<keyword>gemcitabine [ Substance Name ]</keyword>
	<keyword>oxaliplatin [ Substance Name ]</keyword>
	<keyword>gemcitabine-oxaliplatin regimen [ Substance Name ]</keyword>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Multicenter Studies</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Injections , Intra-Arterial</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Chemotherapy , Adjuvant</keyword>
</DOC>